Fezolinetant for Hot Flashes and Brain Health
Treatments studied
Part of Women’s health & pregnancy clinical trials.
This study tests whether fezolinetant, a new medication, can reduce moderate-to-severe hot flashes and night sweats during menopause while protecting heart and brain health. Participants will receive the study drug or placebo and have regular check-ups including brain imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were born female and are between 40 and 65 years old
- You have had at least 7–8 moderate-to-severe hot flashes or night sweats every day for the past week
- You are in menopause: either no periods for 12+ months, or no periods for 6–12 months with a high FSH blood test result
- You have a healthy weight range (BMI between 18–38)
- You are not currently pregnant, breastfeeding, or taking hormone therapy or other hot-flash treatments
- You can safely have an MRI scan and have no history of serious heart, brain, liver, or kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ways to help women during the late menopausal transition. It uses a smartphone app and telehealth visits to track your health and help you feel better.
This study tests whether tirzepatide, a weekly injection, can reduce hot flashes and slow biological aging in postmenopausal women with obesity. It may help if you are experiencing bothersome hot flashes and are willing to follow a diet and exercise plan.
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
This trial tests a new medication called fezolinetant to reduce hot flashes (sudden feelings of intense heat) in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of this treatment, and this study aims to see if fezolinetant can help relieve them.
Hear when a new Menopause Hot Flashes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.